NIH Offers Exclusive License for RXFP1 Agonist Inventions
Published Date: 7/23/2026
Notice
Summary
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Exclusive RXFP1 License to Modala Bio
The National Institutes of Health is contemplating granting Modala Bio an exclusive patent license to novel RXFP1 agonists, with a prospective territory that may be worldwide and a field of use limited to treatments for cancers, cardiovascular, pulmonary, and fibrotic diseases. This exclusive right would give Modala special commercial control over these inventions.
Prospective License Will Be Royalty-Bearing
The notice states the prospective exclusive license to practice the RXFP1 inventions will be royalty-bearing, meaning the licensee would pay royalties to the patent owners or the government under the license terms. This condition applies if the exclusive license is granted.
Deadline to Apply or Comment
If you want to apply for a license or submit comments about the contemplated exclusive license to Modala Bio, your written materials must be received by the National Center for Advancing Translational Sciences on or before August 24, 2026. License applications will be presumed to contain business confidential information, while general comments and objections (not in license applications) may be made publicly available.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
2026-14666, National Institute of Neurological Disorders and Stroke; Notice of Meeting
The National Institute of Neurological Disorders and Stroke is hosting a free, virtual meeting on August 24, 2026, to talk about Parkinson’s disease research, care, and services. This meeting affects people with Parkinson’s, their families, and organizations working on the disease, as it will share updates and plan a federal list of Parkinson’s programs. Public comments are welcome until August 10, giving everyone a chance to join the conversation and help shape future efforts.
2026-14346, Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
The National Cancer Institute has invented a cool new way to grow special immune cells called TCR-T cells that can better fight cancer. This method helps companies make more powerful, targeted cell therapies by boosting the right cells and cutting out the extras. If you’re in biotech or cancer treatment, this is your chance to license a game-changing tool that could speed up cancer cures and bring new treatments to patients faster.
2026-14347, Government Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)
The National Cancer Institute has created a new way to make special immune cells called PILs that can fight chronic HPV infections causing painful growths in the throat and genital areas. This new cell therapy could reduce the need for repeated surgeries, improving patients’ lives and cutting healthcare costs. Researchers are now looking for partners to help develop and license this promising treatment soon.
2026-14242, National Institute on Minority Health and Health Disparities; Notice of Partially Closed Meeting
The National Institute on Minority Health and Health Disparities is holding a virtual meeting on August 31, 2026, to discuss important health topics and review grant applications. The first part of the meeting is open to the public and will be streamed online, while the last hour is closed to protect private info and trade secrets. This meeting affects researchers and communities focused on minority health and could influence future funding decisions.
2026-14133, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering new, powerful antibodies for licensing that help the immune system fight cancer better by releasing its natural brakes. This opportunity is perfect for companies ready to bring cutting-edge cancer treatments to market faster, with some international patent options available. Interested parties should act soon to explore this exciting tech and start making a difference—and money!
Previous / Next Documents
Previous: 2026-14841, Quarterly Publication of Individuals, Who Have Chosen To Expatriate
Every few months, the IRS shares a list of people who gave up their U.S. citizenship or long-term resident status. This update covers those who lost it by June 30, 2026. If you’re thinking about expatriating, know this process is official, public, and can have tax and timing consequences.
Next: 2026-14855, Intent To Request Extension From OMB of One Current Public Collection of Information: Transportation Security Officer Medical Questionnaire
The TSA is asking to keep using its medical questionnaire for Transportation Security Officer (TSO) candidates to make sure they’re fit for the job. They want to extend this paperwork approval and are inviting the public to share thoughts by September 21, 2026. This won’t cost extra money but helps keep airport security strong and safe!